Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 163 SEK 0.74% Market Closed
Market Cap: 12.9B SEK
Have any thoughts about
Biotage AB?
Write Note

Intrinsic Value

The intrinsic value of one BIOT stock under the Base Case scenario is 191.22 SEK. Compared to the current market price of 163 SEK, Biotage AB is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BIOT Intrinsic Value
191.22 SEK
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biotage AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BIOT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BIOT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Biotage AB

Provide an overview of the primary business activities
of Biotage AB.

What unique competitive advantages
does Biotage AB hold over its rivals?

What risks and challenges
does Biotage AB face in the near future?

Has there been any significant insider trading activity
in Biotage AB recently?

Summarize the latest earnings call
of Biotage AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biotage AB.

Provide P/S
for Biotage AB.

Provide P/E
for Biotage AB.

Provide P/OCF
for Biotage AB.

Provide P/FCFE
for Biotage AB.

Provide P/B
for Biotage AB.

Provide EV/S
for Biotage AB.

Provide EV/GP
for Biotage AB.

Provide EV/EBITDA
for Biotage AB.

Provide EV/EBIT
for Biotage AB.

Provide EV/OCF
for Biotage AB.

Provide EV/FCFF
for Biotage AB.

Provide EV/IC
for Biotage AB.

Show me price targets
for Biotage AB made by professional analysts.

What are the Revenue projections
for Biotage AB?

How accurate were the past Revenue estimates
for Biotage AB?

What are the Net Income projections
for Biotage AB?

How accurate were the past Net Income estimates
for Biotage AB?

What are the EPS projections
for Biotage AB?

How accurate were the past EPS estimates
for Biotage AB?

What are the EBIT projections
for Biotage AB?

How accurate were the past EBIT estimates
for Biotage AB?

Compare the revenue forecasts
for Biotage AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biotage AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biotage AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biotage AB compared to its peers.

Compare the P/E ratios
of Biotage AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Biotage AB with its peers.

Analyze the financial leverage
of Biotage AB compared to its main competitors.

Show all profitability ratios
for Biotage AB.

Provide ROE
for Biotage AB.

Provide ROA
for Biotage AB.

Provide ROIC
for Biotage AB.

Provide ROCE
for Biotage AB.

Provide Gross Margin
for Biotage AB.

Provide Operating Margin
for Biotage AB.

Provide Net Margin
for Biotage AB.

Provide FCF Margin
for Biotage AB.

Show all solvency ratios
for Biotage AB.

Provide D/E Ratio
for Biotage AB.

Provide D/A Ratio
for Biotage AB.

Provide Interest Coverage Ratio
for Biotage AB.

Provide Altman Z-Score Ratio
for Biotage AB.

Provide Quick Ratio
for Biotage AB.

Provide Current Ratio
for Biotage AB.

Provide Cash Ratio
for Biotage AB.

What is the historical Revenue growth
over the last 5 years for Biotage AB?

What is the historical Net Income growth
over the last 5 years for Biotage AB?

What is the current Free Cash Flow
of Biotage AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biotage AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biotage AB

Current Assets 1.2B
Cash & Short-Term Investments 318m
Receivables 409m
Other Current Assets 475m
Non-Current Assets 3.6B
Long-Term Investments 25m
PP&E 300m
Intangibles 3.3B
Other Non-Current Assets 29m
Current Liabilities 639m
Accounts Payable 64m
Other Current Liabilities 575m
Non-Current Liabilities 416m
Long-Term Debt 221m
Other Non-Current Liabilities 195m
Efficiency

Earnings Waterfall
Biotage AB

Revenue
2.1B SEK
Cost of Revenue
-774m SEK
Gross Profit
1.3B SEK
Operating Expenses
-961m SEK
Operating Income
351m SEK
Other Expenses
-101m SEK
Net Income
250m SEK

Free Cash Flow Analysis
Biotage AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Biotage reported strong Q1 results with revenues of SEK 480 million, a 33% increase from last year, and a gross margin of 63.1%. Recurring revenues rose significantly to 72%, largely due to the Astrea business, which grew by 78% year-on-year. The Biologics and Advanced Therapeutics division now accounts for 30% of total revenue, up from 4% last year. However, the company faced challenges in meeting the high demand in the peptide business, which prevented additional growth. Biotage is investing in increasing production capacity to meet future demand. Overall, the company is optimistic about continued growth in the peptide segment and new product launches.

What is Earnings Call?
Fundamental Scores

BIOT Profitability Score
Profitability Due Diligence

Biotage AB's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
59/100
Profitability
Score

Biotage AB's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

BIOT Solvency Score
Solvency Due Diligence

Biotage AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
77/100
Solvency
Score

Biotage AB's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIOT Price Targets Summary
Biotage AB

Wall Street analysts forecast BIOT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIOT is 218.03 SEK with a low forecast of 161.6 SEK and a high forecast of 288.75 SEK.

Lowest
Price Target
161.6 SEK
1% Downside
Average
Price Target
218.03 SEK
34% Upside
Highest
Price Target
288.75 SEK
77% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BIOT?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BIOT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BIOT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Biotage AB Logo
Biotage AB

Country

Sweden

Industry

Life Sciences Tools & Services

Market Cap

13B SEK

Dividend Yield

0.98%

Description

Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.

Contact

UPPSALA
Uppsala
Vimpelgatan 5
+4618565900.0
www.biotage.com

IPO

2000-06-30

Employees

497

Officers

Chief Executive Officer & President
Mr. Frederic Vanderhaegen
Chief Financial Officer
Mr. Andrew Kellett
Executive Vice President of Operations
Mr. Anders Wikstrom BSc, CS
EVP of Global Marketing
Raffaella Bombarda
Chief Human Resources & Sustainability Officer
Ms. Petra Duprez
President of Americas & Chief/Head of Americas
Mr. Scott Carr
Show More
Chief Auditor
Mr. Jonas Stahlberg
Executive Vice President of Business Development
Mr. Olof Nord
President of International - EMEA and APAC
Mr. Andreas Juhlin
Executive Vice President of IT & Digitalization
Mr. Magnus Nordstedt
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIOT stock?

The intrinsic value of one BIOT stock under the Base Case scenario is 191.22 SEK.

Is BIOT stock undervalued or overvalued?

Compared to the current market price of 163 SEK, Biotage AB is Undervalued by 15%.

Back to Top